Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis
CONCLUSION: The combination of TACE and sorafenib significantly can improve TTP and PFS, and reduce the level of risk of adverse reactions of unresectable HCC, especially in the combination before TACE.PMID:34628285 | DOI:10.1016/j.tranon.2021.101238
Source: Translational Oncology - Category: Cancer & Oncology Authors: Yanmei Dai Huijie Jiang Hao Jiang Sheng Zhao Xu Zeng Ran Sun Ruoshui Zheng Source Type: research
More News: Cancer & Oncology | Carcinoma | Databases & Libraries | Hepatocellular Carcinoma | Hypertension | Liver Cancer | Science | Skin | Study